WallStSmart

Cencora Inc. (COR)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 1201% more annual revenue ($328.68B vs $25.27B). SYK leads profitability with a 13.2% profit margin vs 0.8%. COR appears more attractively valued with a PEG of 0.73. COR earns a higher WallStSmart Score of 64/100 (C+).

COR

Buy

64

out of 100

Grade: C+

Growth: 7.3Profit: 6.0Value: 8.0Quality: 5.0

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 7.0Value: 4.7Quality: 6.0
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORUndervalued (+71.1%)

Margin of Safety

+71.1%

Fair Value

$1266.50

Current Price

$261.08

$1005.42 discount

UndervaluedFair: $1266.50Overvalued
SYKOvervalued (-10.9%)

Margin of Safety

-10.9%

Fair Value

$265.23

Current Price

$285.47

$20.24 premium

UndervaluedFair: $265.23Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR4 strengths · Avg: 9.0/10
Return on EquityProfitability
107.1%10/10

Every $100 of equity generates 107 in profit

EPS GrowthGrowth
128.3%10/10

Earnings expanding 128.3% YoY

PEG RatioValuation
0.738/10

Growing faster than its price suggests

Free Cash FlowQuality
$1.17B8/10

Generating 1.2B in free cash flow

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.69B9/10

Large-cap with strong market position

Areas to Watch

COR4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.8%4/10

3.8% revenue growth

Profit MarginProfitability
0.8%3/10

0.8% margin — thin

Operating MarginProfitability
1.7%3/10

Operating margin of 1.7%

Price/BookValuation
26.6x2/10

Trading at 26.6x book value

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
34.0x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, EPS Growth, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.39 suggests the stock is reasonably priced for its growth.

Bear Case : COR

The primary concerns for COR are Revenue Growth, Profit Margin, Operating Margin. Thin 0.8% margins leave little buffer for downturns.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

SYK carries more volatility with a beta of 0.81 — expect wider price swings.

COR is growing revenue faster at 3.8% — sustainability is the question.

COR generates stronger free cash flow (1.2B), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

COR scores higher overall (64/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?